Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Clinical trial NCT02831179 · WITHDRAWN

Trial details

NCT number: NCT02831179
Sponsor: Vanderbilt-Ingram Cancer Center
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Functional Pancreatic Neuroendocrine Tumor Malignant Somatostatinoma Merkel Cell Carcinoma Metastatic Adrenal Gland Pheochromocytoma Metastatic Carcinoid Tumor Multiple Endocrine Neoplasia Type 1 Multiple Endocrine Neoplasia Type 2A Multiple Endocrine Neoplasia Type 2B Neuroendocrine Neoplasm Non-Functional Pancreatic Neuroendocrine Tumor Pancreatic Glucagonoma Pancreatic Insulinoma

Start date: 2017-12-01
Primary completion: 2019-02-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.